San Antonio Breast Cancer Symposium | Conference

Disitamab Vedotin Combos Show Efficacy in HER2+ and HER2-Low Breast Cancers

January 17th 2024

Disitamab vedotin alone and with ICIs, TKIs, or other antiangiogenic agents had consistent efficacy in patients with HER2-positive or -low breast cancers.

Endocrine Therapy Response Status Is Necessary for Treatment Planning in HR+/HER2– Early Breast Cancer

December 9th 2023

Beyond genomic testing, endocrine therapy response should be used to determine whether patients with hormone receptor–positive, HER2-negative, N0-1 early breast cancer.

Neoadjuvant Nivolumab Plus Carboplatin/Paclitaxel Elicits High pCR Rates in Early-Stage TNBC

December 8th 2023

Neoadjuvant nivolumab and non–anthracycline containing chemotherapy produced promising pathologic complete response rates regardless of whether nivolumab was administered before or during treatment with carboplatin and paclitaxel in patients with stage I to IIB triple-negative breast cancer.

Dr Schmid on the Use of Perioperative Pembrolizumab in TNBC

December 8th 2023

Peter Schmid, MD, PhD, discusses updated event-free survival findings from the phase 3 KEYNOTE-522 trial of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in patients with early-stage triple-negative breast cancer.

EFS Benefit With Neoadjuvant Pembrolizumab/Chemo Combo, Adjuvant Pembrolizumab Upheld in High-Risk Early TNBC

December 8th 2023

Neoadjuvant pembrolizumab combined with chemotherapy followed by adjuvant pembrolizumab compared with placebo plus chemotherapy continued to show a clinically meaningful improvement in event-free survival in patients with high-risk, early-stage triple-negative breast cancer.

Zanidatamab Triplet Shows Positive PFS Outcomes in HR+/HER2+ Metastatic Breast Cancer

December 8th 2023

Zanidatamab in combination with palbociclib and fulvestrant resulted in positive progression-free survival outcomes and exhibited an acceptable safety profile in patients with hormone receptor–positive, HER2-positive metastatic breast cancer.

Atezolizumab Plus Neoadjuvant HP/Chemo Does Not Significantly Improve pCR in HER2+ Breast Cancer

December 8th 2023

The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.

MammaPrint Predicts Likelihood of pCR With Neoadjuvant Chemo in HR+/HER2– Early Breast Cancer

December 8th 2023

Real-world data support the use of the MammaPrint index as a predictor of neoadjuvant chemosensitivity in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.

Obesity May Contribute to Biological Differences in Breast Cancer Tumors

December 8th 2023

Clinical, transcriptomic, and genomic differences that may contribute to aggressive tumor biology were observed between Latin-American and non-Hispanic White patients with breast cancer.

Adjuvant T-DM1 Provides Sustained Survival Benefit in HER2+ Early Breast Cancer

December 8th 2023

Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial.

SIM0270 Demonstrates Early Antitumor Activity in ER+/HER2– Advanced/Metastatic Breast Cancer

December 8th 2023

The brain-penetrant oral selective estrogen receptor degrader SIM0270 exhibited a favorable safety profile and early signals of antitumor activity in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer, including those with ESR1 mutations.

Ribociclib Plus Nonsteroidal Aromatase Inhibitor Improves iDFS in HR+ HER2- Early Breast Cancer

December 8th 2023

A continued statistically significant improvement in iDFS was observed for patients with HR-positive, HER2-negative early-stage breast cancer who received ribociclib plus a nonsteroidal AI vs a nonsteroidal AI alone, according to the final iDFS analysis of the phase 3 NATALEE trial.

Elacestrant Improves PFS in ESR1-Mutant Metastatic Breast Cancer Subgroups

December 8th 2023

Treatment with elacestrant led to a clinically meaningful improvement in progression-free-survival compared with standard-of-care therapy among patients with estrogen receptor–positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Dr Damodaran on Futibatinib Plus Fulvestrant in FGFR1-Amplified HR+/HER2– Breast Cancer

December 7th 2023

Senthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial.

Trastuzumab Deruxtecan Plus Endocrine Therapy Demonstrates Antitumor Activity in HER2-Low/HR+ Metastatic Breast Cancer

December 7th 2023

Anastrozole or fulvestrant plus fam-trastuzumab deruxtecan-nxki demonstrated encouraging antitumor activity in patients with chemotherapy-naïve, HER2-low hormone receptor–positive metastatic breast cancer.

T-DXd Yields Early Activity in HER2+/HER2-Low Breast Cancer With Leptomeningeal Carcinomatosis

December 7th 2023

Treatment with trastuzumab deruxtecan generated clinical responses in patients with HER2-low or HER2-positive advanced breast cancer with pathologically confirmed leptomeningeal carcinomatosis.

Datopotamab Deruxtecan Prolongs PFS in HR+/HER2- Inoperable or Metastatic Breast Cancer

December 7th 2023

Datopotamab deruxtecan resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy among patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.

T-DXd Demonstrates Real-World Efficacy in Advanced Breast Cancer With Dynamic HER2 Expression

December 7th 2023

Administration of fam-trastuzumab deruxtecan significantly prolonged time-to-next treatment in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course.

Disparities in Survival Outcomes Revealed With BluePrint and MammaPrint Subtyping in HR+/HER2– Breast Cancer

December 7th 2023

Precise stratification of hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays revealed comparable 3-year recurrence-free survival rates between Black and White patients despite observed racial differences in the distribution of molecular subtypes.

Freeman on Mortality Differences Across Racial Groups in Male Patients With Breast Cancer

December 6th 2023

Jason Jincong Freeman, discusses mortality differences across various racial groups in male patients with stage I, II, or III breast cancer.